Treatment of Isolated Internal Mammary Node Metastasis

Primary Treatment Approach

• The National Comprehensive Cancer Network recommends radiation therapy for isolated internal mammary node metastasis, using a base dose of 50 Gy in 1.8-2.0 Gy fractions to the internal mammary chain, targeting the first 3-5 intercostal spaces where internal mammary nodes are most commonly located, with CT-based treatment planning to minimize cardiac and pulmonary toxicity 1, 2, 3
• The American College of Radiology suggests that CT-based treatment planning is essential to minimize cardiac and pulmonary toxicity in patients with isolated internal mammary node metastasis 1, 2, 3

Systemic Therapy Integration

• The European Society for Medical Oncology recommends determining receptor status by biopsy of the internal mammary node to establish ER/PR/HER2 status, and selecting systemic therapy based on biology, with hormone receptor-positive disease treated with endocrine therapy, HER2-positive disease treated with trastuzumab-based therapy combined with chemotherapy, and triple-negative or aggressive disease treated with chemotherapy 4, 5, 6
• The National Comprehensive Cancer Network suggests that systemic therapy should be administered according to standard breast cancer protocols, with radiation therapy typically following chemotherapy 1, 2

Critical Technical Considerations

• The American Society for Radiation Oncology recommends delineating internal mammary node vessels with 7-mm expansion for target volume, and minimizing heart dose by using modern techniques to reduce cardiac exposure 1, 3
• The European Society for Radiotherapy and Oncology suggests including infraclavicular and supraclavicular regions in the radiation field if there is concurrent axillary involvement 1, 2

Monitoring and Follow-up

• The National Comprehensive Cancer Network recommends frequent monitoring every 2-3 months during active treatment, with radiological examinations and tumor markers for response assessment 6